5-azacytosine compounds in medicinal chemistry: Current stage and future perspectives

Future Medicinal Chemistry

Volumn 4, Issue 8, 2012, Pages 991-1005

  Krečmerová, Marcela ^a   Otmar, Miroslav ^a  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXYETHOXY)ETHYL 5 AZACYTOSINE; 1 (2,3 DIHYDROXYPROPYL) 6 AZAISOCYTOSINE; 1 [(2 HYDROXYETHOXY)METHYL] 6 AZAISOCYTOSINE; 1 [2 (PHOSPHONOMETHOXY)ETHYL] 6 AZACYTOSINE; 1 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 5 AZACYTOSINE; 1,2,4 TRIAZINE DERIVATIVE; 2' DEOXY 5,6 DIHYDRO 5 AZACYTIDINE; 3 (9 ADENINYL) 2 HYDROXYPROPIONIC ACID; 5 AZA 1 [(2,3 DIHYDROXYPROPYL)]CYTOSINE; 5 AZA 1 [2 HYDROXY 1 (HYDROXYMETHYL)ETHOXYMETHYL]CYTOSINE; 5 AZA 2' DEOXYCYTIDINE; 5,6 DIHYDRO 2' DEOXY 5 AZACYTIDINE; 5,6 DIHYDROAZACITIDINE; ACICLOVIR; ADEFOVIR; ANTIVIRUS AGENT; AZACITIDINE; AZAURIDINE 5' PHOSPHATE; CIDOFOVIR; CYTARABINE; ERITADENINE; FAMCICLOVIR; FAZARABINE; GANCICLOVIR; KP 1416; KP 1461; NUCLEOSIDE DERIVATIVE; PENCICLOVIR; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; CHEMICAL BOND; CYCLOADDITION; CYTOMEGALOVIRUS RETINITIS; CYTOTOXICITY; DNA METHYLATION; DNA SYNTHESIS; DOWN REGULATION; DRUG HYDROLYSIS; DRUG STRUCTURE; ENANTIOMER; EPIGENETICS; GENE ACTIVATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MESOTHELIOMA; MUTAGENESIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; SUBSTITUTION REACTION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; AZACITIDINE; CYTOSINE; DNA METHYLATION; DRUG DISCOVERY; HIV; HIV INFECTIONS; HUMANS; NEOPLASMS;

EID: 84861893973     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.36     Document Type: Review

References (89)

1. Pískala A, Šorm F. Nucleic acids components and their analogues. Synthesis of 1-glycosyl derivatives of 5-Azauracil and 5-Azacytosine. Collect. Czech. Chem. Commun. 29(9), 2060-2076 (1964).
2. Šorm F, Cihák A, Veselý J. 5-Azacytidine - new highly effective cancerostatic. Experientia 20(4), 202-203 (1964).
3. Hanka LJ, Evans JS, Mason DJ, Dietz A. Microbiological production of 5-Azacytidine. Production and biological activity. Antimicrob. Agents Chemother. 6, 619-624 (1966).
4. Pliml J, Šorm F. Synthesis of 2′-deoxy-d- ribofuranosylazacytosine - Preliminary communication. Collect. Czech. Chem. Commun. 29(10), 2576-2578 (1964).
5. Šorm F, Veselý J. Effect of 5-Aza-2′- deoxycytidine against leukemic and hemopoetic tissues in AKR mice. Neoplasma. 15(4), 339-343 (1968).
6. Pithová P, Pískala A, Pitha J. Nucleic acids components and their analogues. 66. Hydrolysis of 5-Azacytidine and its connection with biological activity. Collect. Czech. Chem. Commun. 30(8), 2801-2811 (1965).
7. Lin K-T, Momparler RL, Rivard GE. High performance liquid chromatographic analysis of chemical stability of 5-Aza-2′- deoxycytidine. J. Pharm. Sci. 70 (11), 1128-1232 (1981).
8. Rogstad DK, Herring JL, Theruvathu JA et al. Chemical decomposition of 5-Aza-2′- deoxycytidine (decitabine): Kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem. Res. Toxicol. 22(6), 1194-1204 (2009).
9. Doskocil J, Paces V, Šorm F. Inhibition of protein synthesis by 5-Azacytidine in Escherichia coli. Biochim. Biophys. Acta 145(3), 771-779 (1967).
10. Paces V, Doskocil J, Šorm F. Incorporation of 5-Azacytidine into nucleic acids of Escherichia coli. Biochim. Biophys. Acta 161(2), 352-360 (1968).
11. Veselý J, Cihák A. 5-Azacytidine: Mechanism of action and biological effects in mammalian cells. Pharm. Ther. 2(4), 813-840 (1978).
12. Veselý J, Cihák A. Incorporation of a potent antileukemic agent, 5-Aza-2′-deoxycytidine, into DNA of leukemic cells from leukemic mice. Cancer Res. 37(10), 3684-3689 (1977).
13. Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-Azacytidine on L1210 leukemia. Cancer Res. 30(11), 2760-2769 (1970).
14. Veselý J, Cihák A, Šorm, F. Metabolic alterations in leukemic mouse cells following 5-Aza-2′-deoxycytidine. Collect. Czech. Chem. Commun. 34(3), 901-909 (1969).
15. Hrodek O, Veselý J. 5-Azacytidine in childhood leukemia. Neoplasma 18(5), 493-503 (1971).
16. Carr BI, Reilly JG, Smith SS. The tumorigenicity of 5-Azacytidine in the male Fisher rat. Carcinogenesis 5(12), 1583-1590 (1984).
17. Carr BI, Riggs A, Reilly JG. Tumorigenicity and cyto-toxicity of 5-Azacytidine and analogs. Br. J. Cancer 50(2), 269-270 (1984).
18. Carr BI, Rahbar S, Asmeron Y, Riggs A, Winberg CD. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. Br. J. Cancer 57 (4), 395-402 (1988).
19. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20 (1), 85-93 (1980).
20. Jones PA, Taylor SM. Hemimethylated duplex DNAs prepared from 5-Azacytidine-treated cells. Nucleic Acids Res. 9 (12), 2933-2947 (1981).
21. Jones PA, Taylor SM, Mohandas T, Shapiro LJ. Cell cycle specific reactivation of an inactive X-chromosome locus by 5-Azadeoxycytidine. Proc. Natl Acad. Sci. USA 79(4), 1215-1219 (1982).
22. Santi DV, Garrett CE, Barr PJ. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell 33(1), 9-10 (1983).
23. Ren J, Singh BN, Huang Q et al. DNA hypermethylation as a chemotherapy target. Cell. Signal. 23(7), 1082-1093 (2011).
24. Yang X, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol. Sci. 31(11), 536-546 (2010).
25. Yoo CB, Jones PA. Epigenetic therapy of cancer: Past, present and future. Nat. Rev. Drug Discov. 5(37), 37-50 (2006).
26. Hollenbach PW, Nguyen AN, Brady H et al. A comparison of azacytidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 5(2), e9001 (2010).
27. Szmigielska-Kaplon A, Robak T. Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia. Curr. Cancer Drug Targets 11(7), 837-848 (2011).
28. Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin. Drug. Metab. Toxicol. 7(5), 661-672 (2011).
29. Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS ONE 6(3), e17338 (2011).
30. Costa R, Abdulhaq H, Haq B et al. Activity of azacytidine in chronic myelomonocytic leukemia. Cancer 117(12), 2690-2696 (2011).
31. Veselý J, Pískala A. Effect of the a-d-Anomer of 5-Aza-2′-deoxycytidine on L1210 mouse leukemic cells in vitro and in vivo. Cancer Res. 44 (11), 5765-5768 (1984).
32. Fojtová M, Pískala A, Votruba I, Otmar M, Bartová E, Kovarík A. Efficacy of DNA hypomethylating capacities and its alpha anomer. Pharmacol. Res. 55 (1), 16-22 (2007).
33. Hájek M, Votruba I, Holý A, Krecmerová M, Tlouštová E. Alpha anomer of 5-Aza-2′- deoxycytidine downregulates hTERT mRNA expression in human leukemia HL-60 cells. Biochem. Pharmacol. 75 (4), 965-972 (2008).
34. Beisler JA, Abbasi MM, Driscoll JS. Synthesis and antitumor activity of 5-Azacytosine arabinoside. J. Med. Chem. 22(10), 1230-1234 (1979).
35. Surbone A, Ford H, Kelley JA et al. Phase I and pharmacokinetic study of arabinofuranosyl-5-Azacytosine (fazarabine, NSC 281272). Cancer Res. 50(4), 1220-1225 (1990).
36. Veselý J, Pískala A. Mechanism of action of 1-b-d-Arabinofuranosyl-5-Azacytosine and its effects in L1210 leukemia cells. Neoplasma 33(1), 3-10 (1986).
37. Townsend A, Leclerc JM, Dutschman G, Cooney DA, Cheng YC. Metabolism of 1-b-d-Arabinosyl-5-Azacytosine and incorporation into DNA of human T-lymphoblastic cells (Molt-4). Cancer Res. 45(8), 3522-3528 (1985).
38. Wilhelm M, O'Brien S, Rios MB et al. Phase I study of arabinosyl-5-Azacytidine (Fazarabine) in adult acute leukemia and chronic myelogenous leukemia in elastic phase. Leukemia Lymphoma 34(5-6), 511-518 (1999).
39. Beisler JA, Abbasi MM, Kelley JA, Driscoll JS. Synthesis and antitumor activity of dihydro-5-Azacytidine, a hydrolytically stable analogue of 5-Azacytidine. J. Med. Chem. 20(6), 806-812 (1977).
40. Kees UR, Avramis VI. Biochemical pharmacology and DNA methylation studies of arabinosyl 5-Azacytidine and 5,6-dihydro- 5-Azacytidine in 2 human leukemia/cell lines PER-145 and PER-163. Anticancer Drugs 6(2), 303-310 (1995).
41. Glazer RI, Peale AL, Beisler JA, Abbasi MM. The effect of 5-Azacytidine and dihydro-5- azacytidine on nuclear ribosomal RNA and poly (A) RNA synthesis in L1210 cells in vitro. Mol. Pharmacol. 17(2), 111-117 (1980).
42. Traganos F, Staiano-Coico L, Darzynkiewicz A, Melamed MR. Effects of dihydro-5- azacytidine on cell survival and cell cycle progression of cultured mammalian cells. Cancer Res. 41 (3), 780-789 (1981).
43. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs, and DNA methylation. Cell 20 (1), 85-93 (1980).
44. Voytek P, Beisler JA, Abbasi MM, Wolpert- DeFillipes MK. Comparative studies of the cytostatic action and metabolism of 5-Azacytidine and 5,6-dihydro-5-Azacytidine. Cancer Res. 37(7), 1956-1961 (1977).
45. Vogelzang NJ, Herndon JE, Cirrincione C et al. Dihydro-5-Azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 79(11), 2237-2242 (1997).
46. Pískala A, Cesneková B, Veselý J. Preparation and biological activity of 5,6-dihydro-5- azapyrimidine nucleosides. Nucleic Acids Res. 18, 57-60 (1987).
47. Harris KS, Brabant W, Styrchak S, Gall A, Daifuku R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral. Res. 67(1), 1-9 (2005).
48. Murakami E, Basavapathruni A, Bradley WD, Anderson KS. Mechanism of action of a novel viral mutagenic covert nucleotide: Molecular interaction with HIV-1 reverse transcriptase and host cell DNA polymerases. Antiviral Res. 67(1), 10-17 2005).
49. Graci JD, Cameron CE. Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol. 3(6), 553-566 (2008).
50. Mullins JI, Heath L, Hughes JP et al. Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461. PLoS ONE 6(1), e15135 (2011).
51. Sheikhnejad G, Brank A, Christman JK et al. Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-Azacytosine. J. Mol. Biol. 285 (5), 2021-2034 (1999).
52. Matoušová M, Votruba I, Otmar M, Tlouštová E, Günterová J, Mertlíková- Kaiserová H. 2′-deoxy-5,6-dihydro-5- azacytidine - A less toxic alternative of 2′-deoxy-5-Azacytidine. Epigenetics 6(6), 769-776 (2011).
53. Pískala A. Nucleic acids components and their analogues. CIV. Methylation of 4-Amino-1,2- dihydro-1,3,5-triazin-2-one (5-Azacytosine). Collect. Czech. Chem. Commun. 32 (12), 4271-4279 (1967).
54. Elion GB, Furman PA, Fyfe JA, De Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl Acad. Sci. USA 74(12), 5716-5720 (1977).
55. Schaeffer HJ, Beauchamp L, De Miranda P, Elion GB, Bauer DJ, Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 272(5654), 583-585 (1978).
56. Superti F, Ammendolia MG, Marchetti M. New advances in anti-HSV chemotherapy. Curr. Med. Chem. 15(9), 900-911 (2008).
57. Boyd MR, Bacon TH, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3- hydroxymethylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob. Agents Chemother. 31(8), 1238-1242 (1987).
58. De Clercq E, Descamps J, De Somer P, Holý A. (S)-9-(2,3- dihydroxypropyl)adenine: An aliphatic nucleoside analog with broad-spectrum antiviral activity. Science 200(4341), 563-565 (1978).
59. De Clercq E, Holý A. Alkyl esters of 3-Adenin-9-yl-2- hydroxypropanoic acid: A new class of broad-spectrum antiviral agents. J. Med. Chem. 28(3), 282-287 (1985).
60. Holý A, Votruba I, De Clercq E. Studies on S-Adenosyl-l- homocysteine hydrolase. Synthesis and antiviral activity of stereoisomeric eritadenines. Collect. Czech. Chem. Commun. 47(5), 1392-1407 (1982).
61. Holý A. Nucleic acid components and their analogs. Synthesis of N-(2,3- dihydroxypropyl) derivatives of heterocyclic bases. Collect. Czech. Chem. Commun. 43(8), 2054-2061 (1978).
62. Holý A. Synthesis of new mono hydroxyalkyl and disubstituted hydroxyalkyl and aminoalkyl derivatives of heterocyclic bases. Collect. Czech. Chem. Commun. 43(12), 3444-3465 (1978).
63. Ogilvie KK, Dixit DM, Radatus BK, Smith KO, Galloway KS. Synthesis of 5-substituted 1-[[2-hydroxy-1-( hydroxymethy1)ethoxy] methyl]cytosines. Nucleosides Nucleotides 2(2), 147-154, (1983).
64. Beauchamp LM, Serling BL, Kelsey JE et al. Effect of acyclic pyrimidines related to 9-[(1,3-dihydroxy-2-propoxy)mehtyl]guanine on herpesviruses. J. Med. Chem. 31(1), 144-149 (1988).
65. Kikelj V, Julienne K, Janvier P, Meslin J-C, Deniaud D. A novel, simple cyclocondensation reaction towards glycosyl triazines. Synthesis (Stuttgart) 21, 3453-3460 (2008).
66. Krecmerová M, Holý A, Pískala A et al. Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy) propyl]cytosine (cidofovir) and related compounds. J. Med. Chem. 50(5), 1069-1077 (2007).
67. Levine HL, Brody RS, Westheimer FH. Inhibition of orotidine-5′- phosphate. Decarboxylase by 1-(5′-phospho-beta-d-ribofuranosyl)barbituric acid, 6-Azauridine 5′-phosphate, and uridine 5′-phosphate. Biochemistry 19 (22), 4993-4999 (1980).
68. Poduch E, Bello AM, Tang S, Fujihashi M, Pai EF, Kotra LP. Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics. J. Med. Chem. 49(16), 4937-4945 (2006).
69. Bello AM, Poduch E, Liu Y et al. Structure-Activity relationships of C6-uridine. Derivatives targeting plasmodia orotidine monophosphate decarboxylase. J. Med. Chem. 51(3), 439-448 (2008).
70. Langley DB, Shojaei M, Chan C et al. Structure and inhibition of orotidine 5′-monophosphate decarboxylase from Plasmodium falciparum. Biochemistry 47(12), 3842-3854 (2008).
71. Al-Etalbi A, Makhseed S, Al-Awadi NA, Ibrahim YA. A novel simple pyrolytic approach towards anhydronucleosides. Tet. Lett. 46(1), 31-35 (2005).
72. El-Barbary AA, Sakran MA, El-Madani AM. Synthesis, characterization and biological activity of some 1,2,4-triazine derivatives. J. Heterocycl. Chem. 42(5), 935-941 (2005).
73. Mansour AK, Eid MM, Khalil NSAM. Selective synthesis and reactions of 6-substituted-2-beta-galactosyl-1,2,4-triazines of potential anticancer activity. Nucleosides Nucleotides Nucleic Acids 22(1), 21-44 (2003).
74. Hwang LC, Wang C-J. Synthesis and structure assignment of 1-[(2-hydroxyethoxy)- methyl]- and 1-[(1,3-dihydroxy-2-propoxy) methyl]-6-Azaisocytosine. Heterocycles 41(2), 293-301 (1995).
75. Tzeng C, Hwang L Chen C, Wei D. Synthesis of racemic 5-substituted 1-(2,3-dihydroxypropyl)-6-Azauracils and their isosteric isomers. Nucleosides Nucleotides. 14(6), 1425-1436 (1995).
76. Holý A. Phosphonomethoxyalkyl analogs of nucleotides. Curr. Pharm. Des. 9(31), 2567-2692 (2003).
77. De Clercq E, Holý A. Acyclic nucleoside phosphonates: A key class of antiviral drugs. Nat. Rev. Drug Disc. 4(11), 928-940, (2005).
78. De Clercq E. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond. Biochem. Pharmacol. 82(2), 99-109 (2011).
79. Holý A, Günter J, Dvoráková H et al. Structure-Antiviral activity relationship in the series of pyrimidine and purine N-[2-(2- phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base. J. Med. Chem. 42(12), 2064-2068 (1999).
80. Berenguer J, Mallolas J. Intravenous cidofovir for compassionate use in AIDS patients with cytomegalovirus retinitis. Clin. Infect. Dis. 30(1), 182-184 (2000).
81. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 16(4), 569-596 (2003).
82. Krecmerová M, Masojídková M, Holý A. Acyclic nucleoside phosphonates with 5-Azacytosine base moiety substituted in C-6 position. Bioorg. Med. Chem. 18(1), 387-395 (2010).
83. Dracínský M, Krecmerová M, Holý A. Study of chemical stability of antivirally active 5-Azacytosine acyclic nucleoside phosphonates using NMR spectroscopy. Bioorg. Med. Chem. 16(14), 6778-6782 (2008).
84. Naesens L, Andrei G, Votruba I et al. Intracellular metabolism of the new antiviral compound, 1-(S)-[3-hydroxy-2- (phosphonomethoxy)propyl]-5- Azacytosine. Biochem. Pharmacol. 76(8), 997-1005 (2008).
85. Krecmerová M, Holý A, Pohl R et al. Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2- phosphonomethoxy)propyl]-5-Azacytosine: Synthesis and antiviral activity. J. Med. Chem. 50 (23), 5765-5772 (2007).
86. Andrei G, Krecmerová M, Holý A et al. In vivo antiviral activity of 1-(S)-[3-hydroxy- 2-(phosphonomethoxy)propyl]-5-Acytosine and its cyclic form. Antiviral Res. 74(3), A33-A34 (2007).
87. Lebeau I, Andrei G, Krecmerová M, De Clercq E, Holý A, Snoeck R. Inhibitory activity of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate SV 40 strains. Antimicrob. Agents Chemother. 51(6), 2268-2273 (2007).
88. Topalis D, Lebeau I, Krecmerová M, Andrei G, Snoeck R. Activity of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells. Antimicrob. Agents Chemother. 55(5), 1961-1967 (2011).
89. Otmar M, Dracínský M, Krecmerová M, Balzarini J, Andrei G, Snoeck R. Synthesis of O2- and N3-(2-phosphonomethoxy)ethyl derivatives of 6-phenyl and 6-pyridinyl-5- azacytosine. Heterocycles 83(4), 797-813 (2011).